KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial.

Wenjing Wu, Yaping Yang, Haizhu Chen, Yongkui Lu, Yinduo Zeng, Jianli Zhao, Caiwen Du, Ying Lin, Peijian Peng, Mei Huang, Ying Zhang, Quchang Ouyang, Linxiaoxiao Ding, Ziliang Cheng, Yuanyu Wen, Zhiyong Wu, Jinhui Ye, Li Ling, Kun Wang, Ying Lu, Guorong Zou, Jincai Zhong, Hong Wang, Daren Lin, De Zeng, Chengcai Yao, Qianjun Chen, Liqun Zou, Shusen Wang, Yunfang Yu, Zhongyu Yuan, Ying Wang, Herui Yao

Signal Transduct Target Ther 11(1) 191

PMID42168151
PMCIDPMC13194736
DOI10.1038/s41392-026-02720-6
发表日期2026-05-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Maintenance therapy is key in prolonging remission and improving quality of life for hormone receptor-positive (HR + ), HER-2 negative (HER2-) metastatic breast cancer (MBC), but optimal strategies remain debated. This multicenter, open-label, randomized phase 3 trial conducted across 22 hospitals in mainland China (ClinicalTrials.gov, NCT04263298; Chinadrugtrials.org.cn, ChiCTR-IIR-17014036) compared the efficacy and safety of fulvestrant versus capecitabine as maintenance therapy in HR + /HER2- MBC patients after achieving objective response or disease control following first-line chemotherapy. The primary end point was investigator-assessed progression-free survival (PFS). A total of 210 patients underwent randomization, with 105 assigned to each group. As of the data cutoff date on March 1, 2025, the median follow-up was 33.6 months (range 1.5-81.1). Median PFS favored fulvestrant compared with capecitabine (17.3 months [95% CI 12.7-23.3] vs. 9.0 months [95% CI 7.5-14.3]; hazard ratio 0.63, 95% CI 0.47-0.99; p = 0.003). Overall survival data were not yet mature. Grade ≥3 adverse events (AEs) occurred in three patients (2.9%) in the fulvestrant group and 11 (10.5%) in the capecitabine group. Treatment discontinuation due to AEs occurred in 0% and 7.6% of patients, respectively. Fulvestrant maintenance therapy significantly improves PFS compared to capecitabine in HR + /HER2- MBC patients achieving objective response or disease control following first-line chemotherapy, with a favorable safety profile.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2 Progression-free survival in the full analysis set. Note: The short vertical lines represent censored data

Progression-free_survival_in_the_full_analysis_set

Progression-free survival

Fig. 2 · Panel Progression-free_survival_in_the_full_analysis_set

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Progression-free_survival_in_the_full_analysis_set 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

Fig. 3

Fig. 3 Total progression-free survival (tPFS) and total overall survival (tOS) in the full analysis set. a tPFS; b tOS. The short vertical lines represent censored data. Note: tPFS was defined as the time from initiation of first-line chemotherapy to disease progression, death, or the latest follow-up. tOS was defined as the time from initiation of first-line chemotherapy to death from any cause or the latest follow-up

A

Total progression-free survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Total overall survival

Fig. 3 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Recruitment, randomization, and flow of trial participants
非 KM Figure
Fig. 4Fig. 4 Subgroup analysis of progression-free survival. PR, progesterone receptor; ET, endocrine therapy; CR, complete response; PR, partial response; SD, stable disease
非 KM Figure